Study of volrustomig for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests a new drug called volrustomig, alone or with other cancer treatments, for people with advanced or metastatic solid tumors. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has spread or cannot be removed by surgery.
- You are in relatively good health (able to do daily activities) and have a life expectancy of at least 12 weeks.
- You have not had certain prior treatments (like immunotherapy) or are not currently on other cancer therapies.
- You do not have active infections, autoimmune diseases, or untreated brain metastases (depending on the sub-study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Hear when a new Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.